Zomedica Corp. (ZOM)

2.0500 +0.1600 (+8.47%) At close: 4:00PM EST

Zomedica Corp.

100 Phoenix Drive
Suite 180
Ann Arbor, MI 48108
United States
734 369 2555
http://zomedica.com

Sector(s): Healthcare
Industry: Drug Manufacturers—Specialty & Generic
Full Time Employees: 28

Key Executives

Name	Title	Pay	Exercised	Year Born
Dr. Stephanie Laine Morley D.V.M., DVM	Pres & Chief Medical Officer	263.37k	N/A	1975
Mr. Bruk Herbst	Chief Commercial Officer	N/A	N/A	1969
Mr. Robert Cohen	CEO & Director	N/A	N/A	1958
Ms. Ann Marie Cotter CPA	CFO & Sec.	N/A	N/A	1970
Mr. Michael Schilk	VP of Sales	N/A	N/A	N/A
Mr. David Eaton	VP of Marketing	N/A	N/A	N/A
Dr. William Carpenter MacArthur	Consultant	N/A	N/A	1963
Mr. Robert W. DiMarzo	Consultant	N/A	N/A	1957

Amounts are as of December 31, 2019 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Zomedica Corp., a development stage veterinary diagnostic and pharmaceutical company, engages in the discovery, development, and commercialization of pharmaceuticals for the companion pet. Its lead drug product candidate is ZM-007, an oral suspension formulation of metronidazole for the treatment of acute diarrhea in small dog breeds and puppies. The company is also developing ZM-012, a tablet formulation of metronidazole targeting the treatment of acute diarrhea in dogs; ZM-006, a transdermal gel formulation of methimazole targeting hyperthyroidism in cats; and ZM-011, a transdermal gel formulation of fluoxetine for the treatment of feline behavioral disorders, such as inappropriate urination. It has a collaboration agreement with Celsee, Inc. for the development and commercialization of liquid biopsy assays and related consumables for the detection of cancer in companion animals; and with Seraph Biosciences, Inc. for development and commercialization of novel pathogen detection system. The company was formerly known as Zomedica Pharmaceuticals Corp. and changed its name to Zomedica Corp. in October 2020. Zomedica Corp. was founded in 2015 and is headquartered in Ann Arbor, Michigan.

Corporate Governance

Zomedica Corp.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.